Related Experiment Video
Updated: Jan 15, 2026

Defining Substrate Specificities for Lipase and Phospholipase Candidates
Published on: November 23, 2016
Novel Substituted Spiro-Ureas as Monoacylglycerol Lipase Inhibitors
Jian Rong1,2, Steven H Liang2,3
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan Hubei 430022, P. R. China.
Abstract:
This patent describes novel spiro-ureas as a novel class of monoacylglycerol lipase (MAGL) inhibitors. It provides details on the novel substituted spiro-ureas, pharmaceutical composition, and therapeutic applications for diseases associated with MAGL dysregulation.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Sulfonylureas
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Biosynthesis of Lipids

